Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.65 |
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2317846 | 0.95 | ALDH1A1 (0.71) | ALDH1A1TSHRPOLBRAB9ANPC1 | |
| SCHEMBL2359496 | 0.81 | WNT3A (0.54) | POLB | |
| SCHEMBL2320292 | 0.79 | ALDH1A1 (0.51) | ALDH1A1TSHRPOLBSMN1; SMN2KDM4E | |
| SCHEMBL2317080 | 0.79 | RAB9A (0.56) | ALDH1A1TSHRPOLBRAB9ANPC1 | |
| SCHEMBL14995363 | 0.78 | TSHR (1.00) | ALDH1A1TSHRPOLBRAB9ASMN1; SMN2 | |
| SCHEMBL2317227 | 0.78 | ALDH1A1 (0.57) | ALDH1A1TSHRPOLBSMN1; SMN2KDM4E | |
| SCHEMBL2316385 | 0.77 | POLB (0.64) | ALDH1A1TSHRPOLBRAB9ANPC1 | |
| SCHEMBL2417106 | 0.77 | POLB (0.57) | ALDH1A1TSHRPOLBRAB9ANPC1 | |
| SCHEMBL2318727 | 0.77 | POLB (0.57) | ALDH1A1TSHRPOLBRAB9ANPC1 | |
| SCHEMBL2418895 | 0.77 | POLB (0.64) | ALDH1A1TSHRPOLBRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| EP-2352730-A2 | BIOLOGICALLY ACTIVE AMIDES | H. Lundbeck A/S (DK) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010053861-A2 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | NPY5R, NPY1R, NPY2R | ALDH1A1 3024/4885TSHR 209/4885POLB 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.